A. Cho et al., Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells, ART THROM V, 20(12), 2000, pp. 2527-2532
Expression of matrix metalloproteinase (MMP)-9 has been linked to the progr
ession of plaque rupture and intimal formation in arterial lesions. In this
study, we determined which factors and signaling pathways are involved in
regulating the MMP-9 gene. Rat carotid arterial smooth muscle cells treated
with tumor necrosis factor (TNF)-alpha showed a marked increase in MMP-9 a
ctivity and mRNA level, whereas platelet-derived growth factor (PDGF) showe
d a slight induction of the MMP-9 mRNA level. TNF-cr treatment caused an in
crease in c-Jun N-terminal kinase (JNK), p38 mitogen-activated protein kina
se (p38 MAPK), and extracellular signal-regulated kinase (ERK) activities,
whereas PDGF treatment caused an increase in ERKs and p38 MAPK activities w
ithout any effect on JNK activity. Treatment with either SB203580 (inhibito
r of p38 MAPK) or U0126 (inhibitor of the ERK pathway) downregulated the TN
F-alpha -induced MMP-9 expression in a dose-dependent manner. Treatment of
cells with TNF-alpha and PDGF together stimulated the MMP-9 expression at a
level higher than that observed with either factor alone, suggesting that
TNF-alpha and PDGF have a synergistic effect on MMP-9 expression in arteria
l smooth muscle cells. Furthermore, suboptimal inhibitory concentrations of
SB203580 and U0126 together almost completely inhibited the MMP-9 expressi
on. These results suggest that p38 MAPK and ERK pathways contribute to the
transcriptional regulation of MMP-9 in arterial smooth muscle cells.